Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats post-transplant cytomegalovirus (CMV) infection/disease. Sold as Livtencity. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Maribavir (sold as Livtencity), first approved Nov 23, 2021, with 1 new use approved and 0 published complete response letters.
First approved: Nov 23, 2021
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $79.4M
Orphan exclusivity until: Nov 23, 2028
First approved in the EU: Nov 9, 2022
First approved in Japan: Jun 24, 2024
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
First approved in Japan 31 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Livtencity, new ingredientA drug with a new active ingredient indicated for the treatment of cytomegalovirus disease in organ transplantation (including hematopoietic stem cell… · Takeda Pharmaceutical Company Limited · Jun 24, 2024 · Review report
Clinical Trials
8 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
CMV-CMI in csCMVi After HSCTCytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT) · The First Affiliated Hospital of Soochow University
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA